Atropine endpoints and intermediate syndrome after chlorpyrifos poisoning
A 42-year-old male farm worker is brought to the emergency department 90 minutes after his sleeve soaked with a concentrated chlorpyrifos formulation while spraying without protective equipment. He has copious salivation and bronchorrhea, pinpoint pupils, generalised fasciculations, generalised weakness and confusion. Heart rate is 48/min, blood pressure 90/60 mmHg, respiratory rate 28/min and SpO2 88% on room air. Plasma butyrylcholinesterase is 18% and red-cell acetylcholinesterase 22% of the laboratory's reference mean. He is decontaminated and given atropine 2 mg IV boluses repeated every 5 minutes plus pralidoxime 1 g IV over 30 minutes followed by an infusion. Six hours later secretions are controlled and the heart rate is 120/min, but the pupils remain 2 mm and he has developed flaccid weakness of the neck flexors with a falling vital capacity. Total atropine given is 25 mg, and the resident proposes escalating atropine until the pupils dilate.
1. Is pupil size a valid endpoint for atropinisation in this patient? State the endpoints you would actually titrate atropine to, and explain at receptor level why atropine cannot correct the fasciculations and weakness.
Read the worked answer
Pupil size is not a valid titration endpoint. In organophosphate poisoning, miosis is produced by acetylcholine at the iris sphincter, and locally absorbed or circulating inhibitor can keep the pupil constricted even when systemic muscarinic blockade is adequate; conversely, a dilated pupil may simply mean enough atropine has been given. Titrating to mydriasis therefore drives the patient into atropine toxicity - delirium, hyperthermia, ileus, urinary retention, tachycardia - and, worse, can distract from worsening respiratory muscle weakness.
The endpoints that matter are the ones reflecting the lethal effect, which is drowning in secretions: cessation of bronchorrhea and salivation (chest clear on auscultation, no crepitations), heart rate above 80/min, warm dry skin, systolic pressure above 90 mmHg and adequate oxygenation and ventilation. The weakness and fasciculations are nicotinic. Acetylcholine at the neuromuscular junction acts on Nm receptors, and at autonomic ganglia and the adrenal medulla on Nn receptors; atropine is a competitive antagonist only at muscarinic receptors. No dose of atropine will reverse fasciculations, muscle weakness or respiratory muscle paralysis, so the falling vital capacity must not be treated by escalating atropine. The resident should stop escalating once secretions are controlled, and the cumulative dose (25 mg is large but not exceptional) should be recorded and reviewed with the weakness managed as a separate problem.
2. Justify continuing pralidoxime at 6 hours and beyond, and explain what 'ageing' means for this particular compound.
Read the worked answer
Pralidoxime works by nucleophilic attack on the phosphorus atom of the phosphorylated serine in the active site, removing the phosphyl group and regenerating active acetylcholinesterase; it also reduces the atropine requirement and improves nicotinic signs. Its usefulness is time-limited by ageing: after inhibition, the alkoxy group on the phosphorus can dealkylate, leaving a monoalkyl phosphyl-enzyme that is refractory to oxime.
The rate of ageing is a property of the inhibitor. With soman it is minutes; with diethylphosphoryl inhibitors such as chlorpyrifos-oxon it is slow, with a half-life of the order of tens of hours. At 6 hours, therefore, a substantial fraction of enzyme is still reactivatable and continuing the infusion is rational, not futile. Oxime is most effective when started early, before a large pool of aged enzyme accumulates.
Continuing weakness at 6 hours should not be read as evidence of ageing. Alternative explanations are ongoing absorption from a skin or fat depot, an inadequate oxime dose, or the intermediate syndrome. Practical points: keep the infusion running for at least 24-48 hours or until nicotinic signs resolve; monitor for oxime-related hypertension and laryngospasm with rapid injection; reduce the dose in renal impairment because pralidoxime is cleared renally. Document the time from exposure - it is the single best predictor of oxime responsiveness.
3. The vital capacity is falling. What is the likely diagnosis, when does it typically appear, and how does it change your management?
Read the worked answer
Falling vital capacity with neck flexor weakness in a patient whose secretions are controlled points to the intermediate syndrome, not to under-atropinisation. It typically appears 24-96 hours after exposure, after the acute cholinergic crisis has settled, and is characterised by weakness of proximal limb muscles, neck flexors, cranial nerve-innervated muscles (ptosis, dysphagia, facial weakness) and the respiratory muscles. It is not reversed by atropine or by oxime, and its danger is respiratory failure.
Management therefore changes from antidote titration to ventilatory support. The patient needs an ICU, serial measurement of vital capacity and inspiratory force, and intubation before exhaustion rather than after. Succinylcholine must be avoided for intubation because plasma butyrylcholinesterase is inhibited, so the depolarising block will be prolonged; a non-depolarising agent at reduced dose, or another technique, is preferred. Sedatives and respiratory depressants should be minimised. The weakness usually recovers over days to weeks with supportive care.
Two later complications belong on the follow-up plan: organophosphate-induced delayed polyneuropathy, a distal flaccid sensorimotor neuropathy appearing 2-3 weeks after exposure from inhibition of neuropathy target esterase, and delayed neuropsychiatric effects. The resident's plan to keep escalating atropine is not merely unhelpful - it delays the intervention that actually keeps the patient alive.